Quantcast

AzurRX Biopharma prices downsized $5 million IPO at lowered price of $5.50


Shutterstock photo

AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, raised $5 million by offering 0.96 million shares at $5.50. AzurRX Biopharma plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1 Financial Securities acted as lead managers on the deal.

The article AzurRX Biopharma prices downsized $5 million IPO at lowered price of $5.50 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: News Headlines , IPOs
Referenced Symbols: AZRX



More from Renaissance Capital

Subscribe







Renaissance Capital
Contributor:

Renaissance Capital

IPOs












Research Brokers before you trade

Want to trade FX?